Aufklappen
Schliessen
Branche BiotechnologieAktienmarkt Sonstige |
|
|
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
| Leser | Medien | |
|---|---|---|---|---|
| 13.09. | Active Biotech: Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Huntington's Disease Network (EHDN) plenary meeting 2018" | 6 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at the scientific conference "European Huntington's Disease Network (EHDN) plenary... ► Artikel lesen | ||||
| 05.09. | Teva bails on laquinimod, returns rights to Active Biotech | 26 | Seeking Alpha | |
► Artikel lesen | ||||
| ACTIVE BIOTECH Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten! | LYNX | |||
► Artikel lesen | ||||
| 05.09. | Active Biotech regains global rights to development and commercialization of laquinimod | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASELund Sweden, September 5, 2018 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that it regains the global development and commercialization rights to laquinimod from Teva... ► Artikel lesen | ||||
| 09.08. | Active Biotech AB - Interim Report January - June 2018 | 6 | GlobeNewswire (Europe) | |
| Second quarter in brief
The company's... ► Artikel lesen | ||||
| 31.07. | Active Bio and Teva's laquinimod fails once more, now in Huntington's disease | 24 | FierceBiotech | |
► Artikel lesen | ||||
| 31.07. | Active Biotech provides update on laquinimod in Huntington's disease | 4 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Lund Sweden, July 31, 2018 -Active Biotech (NASDAQ OMX NORDIC: ACTI) today provided an update regarding the clinical development of laquinimod by Teva Pharmaceutical... ► Artikel lesen | ||||
| 31.05. | Number of shares and votes in Active Biotech | 8 | GlobeNewswire (Europe) | |
| The number of shares and votes in Active Biotech has changed as a result of the recently completed rights issue.
Today, the last trading day of the month, there are in total 145,236,480 shares... ► Artikel lesen | ||||
| 18.05. | Annual General Meeting of Active Biotech AB | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
The Annual General Meeting of Active Biotech was held on May 17, 2018.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be... ► Artikel lesen | ||||
| 17.05. | Active Biotech AB Interim report January - March 2018 | 4 | GlobeNewswire (Europe) | |
| First quarter in brief
Decision on new share issue with preferential rights for shareholders taken at Extraordinary General Meeting on March 19, 2018
Patent... ► Artikel lesen | ||||
| 04.05. | Nasdaq Stockholm AB: Delisting of paid subscription shares in Active Biotech AB (62/18) | 2 | GlobeNewswire | |
| The paid subscription shares in Active Biotech AB will be delisted. Last
trading day for ACTI BTA is May 8, 2018.
Instrument: Paid subscription shares
---------------------------------------
Short... ► Artikel lesen | ||||
| 23.04. | Annual Report 2017 Active Biotech AB (publ) | 8 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech's Annual Report 2017 is now available för download at www.activebiotech.com (http://www.activebiotech.com).
The Annual Report will only be... ► Artikel lesen | ||||
| 18.04. | Active Biotech: Notice of Annual General Meeting of Shareholders | 10 | GlobeNewswire (Europe) | |
| The Board of Directors of Active Biotech AB (publ) has issued a notice to the Annual General Meeting, which is to take place on Thursday, May 17, 2018, at 5 pm at the company's offices, Scheelevägen... ► Artikel lesen | ||||
| 12.04. | Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer | 11 | GlobeNewswire (Europe) | |
| PRESS RELEASELund, April 12, 2018 - Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces that its partner NeoTX Therapeutics Ltd. will present new data for ANYARA (Naptumumab Estafenatox) at... ► Artikel lesen | ||||
| 27.03. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares in Active Biotech AB (38/18) | 6 | GlobeNewswire | |
| With effect from March 28, 2018, the subscription rights in Active Biotech AB
will be quoted on the list for Equity rights. Quotation will continue up until
and including April 9, 2018.
Instrument:... ► Artikel lesen | ||||
| 22.03. | NASDAQ OMX Nordic: Derivatives: Adjustment in Active Biotech due to rights issue (02/18) | 4 | GlobeNewswire | |
| Extraordinary General Meeting (EGM) of Active Biotech AB (Active Biotech) held
on March 19, 2018, approved a rights issue whereby shareholders are entitled to
one (1) new share for every two (2) shares... ► Artikel lesen | ||||
| 22.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 23.03.2018 - 1 | 56 | Xetra Newsboard | |
| FOLGENDE WERTPAPIERE WERDEN AM 22.03.2018 CUM KAPITALMASSNAHME UND AM 23.03.2018 EX KAPITALMASSNAHME GEHANDELT. THE FOLLOWING SHARES ARE TRADED CUM CAPITAL ADJUSTMENT ON 22.03.2018 AND EX CAPITAL ADJUSTMENT... ► Artikel lesen | ||||
| 15.02. | NASDAQ OMX Nordic: Derivatives: Anticipated adjustment in Active Biotech due to rights issue (01/18) | 6 | GlobeNewswire | |
| The following information is based on a press release from Active Biotech AB
(Active Biotech) published on February 15, 2018 and may be subject to change.
The board of Active Biotech has proposed... ► Artikel lesen | ||||
| 15.02. | Active Biotech: NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING | 10 | GlobeNewswire (Europe) | |
| The shareholders of Active Biotech AB (publ) are invited to the Extraordinary Shareholders' Meeting to be held on Monday 19 March 2018, at 5 pm at the company's offices, Scheelevägen 22 in Lund... ► Artikel lesen | ||||
| 15.02. | Active Biotech AB Year-end report January - December 2017 | 5 | GlobeNewswire (Europe) | |
| Fourth quarter in brief
The primary clinical endpoint was not met in the Phase II study (ARPEGGIO) with laquinimod in PPMS
Patent regarding tasquinimod for the... ► Artikel lesen | ||||
| 20.12.17 | Active Biotech: Active Biotech provides updated information about the company's financial position | 7 | GlobeNewswire (Europe) | |
| PRESS RELEASE
Active Biotech has received a waiver (exemption) from its commitment to the bank that finances the company's property in Lund that the company's liquidity should never fall below... ► Artikel lesen | ||||
Seite:
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten:
VerkaufenHaltenKaufen
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | |
|---|---|---|---|---|
| EVOTEC | 17,335 | +2,24 % | Evotec: Es wäre eine Chance … | |
| Das sieht schon interessant aus, was der Chart der Evotec-Aktie (ISIN: DE0005664809) da momentan zeigt. Es könnte sein, dass hier erst einmal ein Boden gefunden ist. Das ist die gute Nachricht. Dass... ► Artikel lesen | ||||
| MEDIGENE | 11,03 | -0,63 % | Medigene: aussichtsreiche Phase 1/2-Studie | |
| Medigene setzt die laufende Phase 1/2-Studie mit dem DC-Impfstoff (DCs = Dendritische Zellvakzine) zur Behandlung der akuten myeloischen Leukämie (AML) weiter fort. Das Management der deutschen Biotech-Gesellschaft... ► Artikel lesen | ||||
| MORPHOSYS | 84,10 | +0,30 % | Evotec und Morphosys nach der Korrektur - war's das? | |
| Die beiden deutschen Vorzeige-Biotechwerte Evotec und Morphosys haben nach einer bislang enorm starken Entwicklung in diesem Jahr zuletzt ordentlich Federn lassen müssen. Dabei rutschten beide Werte... ► Artikel lesen | ||||
| BB BIOTECH | 60,40 | -0,33 % | BB Biotech mit erheblichem Gewinnrückgang - darum ist das relativ normal | |
| Die Schweizer Biotech-Beteiligungsgesellschaft BB Biotech (WKN: A0NFN3) hat zum Ende der letzten Woche vorläufige Zahlen für die ersten neun Monate des Geschäftsjahres 2018 präsentiert. Obwohl die Gewinne... ► Artikel lesen | ||||
| QIAGEN | 30,47 | +0,40 % | QIAGEN sollte weiterhin übergewichtet werden! | |
| New York (www.aktiencheck.de) - QIAGEN-Aktienanalyse des Analysten Steve Beuchaw von Morgan Stanley: Aktienanalyst Steve Beuchaw vom Investmenthaus Morgan Stanley rät laut einer Aktienanalyse nach wie... ► Artikel lesen | ||||
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und mit der Push-Technologie von
Nachrichten • Aktienkurse • DAX • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer | Datenschutz • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage